We are committed to bringing meaningful therapeutic options to patients, healthcare providers, and payers. Our pipeline includes clinical and early-stage product candidates
Our product candidate pipeline includes early-stage product candidates, including recently acquired TCR TReg platform and two novel neuromuscular blocking agents (NMBAs) and a related proprietary chemical reversal agent.